Riboflavin Side Effects

Reported Riboflavin side effects

Riboflavin has an exceptionally clean safety profile — it is among the safest vitamins known, with no established tolerable upper intake level and no reported organ toxicity even at gram-per-day doses used for genetic transport disorders. The saturable intestinal absorption (~20-27 mg maximum per single oral dose) means that much of a high oral dose is not absorbed and passes into the colon or is excreted — excess is efficiently cleared via the kidneys as unmetabolized riboflavin, producing the characteristic bright yellow-orange fluorescent urine that users often notice within hours of taking a supplement. This urinary color is cosmetic only and carries no clinical significance. Similarly, perspiration and other body secretions can take on a faint yellow tint at high intakes. Minor adverse effects at pharmacologic oral doses include occasional nausea, mild diarrhea, and rarely itching at oral riboflavin 200-400 mg/day for migraine prophylaxis. These are uncommon and generally do not require discontinuation. Splitting the daily dose into 200 mg BID or 100 mg QID reduces GI upset in sensitive individuals. Photosensitivity has been reported rarely at pharmacologic doses — patients on migraine-dose riboflavin should use reasonable sun protection, though severe photosensitivity reactions are unusual. Drug interactions. Phenothiazines (chlorpromazine and related antipsychotics), tricyclic antidepressants (amitriptyline, imipramine, nortriptyline), and doxorubicin chemotherapy compete with riboflavin for intestinal transport and cellular phosphorylation; patients on long-term phenothiazine or TCA therapy may have increased riboflavin requirement. Probenecid reduces renal clearance of riboflavin. Oral contraceptives modestly reduce circulating riboflavin. Anticonvulsants (phenobarbital, phenytoin) increase riboflavin catabolism. Chronic alcohol impairs absorption, phosphorylation, and storage. Antibiotics (sulfonamides, tetracyclines) can interact through competing transport. Drug-nutrient interaction of clinical interest: riboflavin + phototherapy. Neonatal jaundice phototherapy using blue-light wavelengths destroys plasma riboflavin, producing a transient riboflavin deficiency that has been associated with photolysis-induced hemolysis in some case series. Parenteral nutrition bags containing riboflavin must be shielded from light during infusion to prevent riboflavin degradation and reactive oxygen species generation. Topical riboflavin for corneal crosslinking is generally well-tolerated. Expected post-procedure effects include 24-48 hours of moderate eye pain, photophobia, tearing, and blurred vision during corneal re-epithelialization. Rare serious adverse effects include sterile corneal infiltrates, corneal haze, infectious keratitis, corneal melting, and endothelial decompensation — these are predominantly associated with infection risk during the de-epithelialized period. Post-procedure use of a bandage contact lens, topical antibiotic, and topical anesthetic/NSAID as directed by the ophthalmologist minimizes these risks. Pregnancy and lactation. RDA-range riboflavin (1.4 mg/day in pregnancy, 1.6 mg/day in lactation) is safe and required. Pharmacologic doses for migraine prophylaxis (400 mg/day) have not been specifically studied in large pregnancy cohorts, but the excellent general safety profile, lack of reported teratogenicity, and limited alternatives for migraine preventive therapy in pregnancy make it a reasonable choice under obstetric/neurology supervision. Breastfeeding: RDA-range riboflavin supports maternal and infant needs; high-dose maternal riboflavin has not been associated with infant adverse effects. Pediatric use. RDA-range riboflavin is essential. Migraine prophylaxis with riboflavin 200-400 mg/day in children and adolescents has modest evidence and is widely used given the excellent safety profile. Brown-Vialetto-Van Laere syndrome and riboflavin-responsive MADD pediatric high-dose protocols (up to 80 mg/kg/day) are managed by metabolic specialists. Laboratory monitoring for chronic pharmacologic riboflavin use is minimal because of the excellent safety profile. Erythrocyte glutathione reductase activity coefficient (EGRAC) is the functional assay of riboflavin status; plasma riboflavin is less sensitive. Routine monitoring is unnecessary for standard migraine-dose use. No withdrawal syndrome is associated with riboflavin discontinuation. The cleanest safety summary: riboflavin is one of the safest vitamins at any clinically used dose; the yellow-orange urinary fluorescence is cosmetic-only; drug interactions exist but are rarely clinically significant; topical corneal crosslinking is well-tolerated under ophthalmological supervision; no organ toxicity has been established even at gram-per-day doses.

When to continue, reduce, or stop Riboflavin

Riboflavin contraindications

There are no absolute contraindications to oral riboflavin at RDA-range or pharmacologic doses; the vitamin has an exceptionally clean safety profile. Relative contraindications and cautions: Known hypersensitivity to riboflavin or to excipients in a particular formulation. Pregnancy: RDA-range riboflavin (1.4 mg/day) is safe and required; pharmacologic doses for migraine prophylaxis (400 mg/day) have not been systematically studied in large pregnancy cohorts but have an excellent general safety profile and are reasonable under obstetric/neurology supervision; lacking prospective RCT data, some clinicians prefer to use dietary and lower-dose options first in pregnancy. Breastfeeding: RDA to modest pharmacologic doses are safe; high-dose protocols for specific genetic disorders require specialist supervision. Pediatric use: RDA-range riboflavin is essential; pharmacologic doses for migraine prophylaxis (200-400 mg/day) have modest evidence and are widely used given safety; high-dose protocols for BVVL, MADD, and GA1 are pediatric metabolic specialist territory. Phenothiazine, tricyclic antidepressant, or doxorubicin therapy: increased riboflavin requirement possible; not a contraindication but may warrant monitoring. Photodynamic therapy with other photosensitizers: corneal crosslinking with riboflavin + UVA should not be combined with other photosensitizing agents. Active herpes simplex keratitis is a relative contraindication to corneal crosslinking (risk of reactivation). Corneal thickness <400 microns after epithelial removal is a contraindication to standard-intensity UVA crosslinking (risk of endothelial damage); hypotonic riboflavin swelling can compensate in borderline cases. No clinically important absolute drug-drug contraindications to oral riboflavin supplementation. Renal failure: riboflavin is renally cleared but has no reported accumulation toxicity; no dose adjustment generally needed for oral supplementation. Hepatic failure: riboflavin phosphorylation occurs predominantly in peripheral tissues rather than liver; no dose adjustment needed for mild-moderate hepatic impairment. The principal practical caution is to choose appropriate dose for indication: RDA range for general adequacy, 1.6 mg/day for MTHFR 677TT BP indication, 400 mg/day for migraine prophylaxis, and kg-weight-based high doses for specific genetic disorders under specialist care.

Why vendor quality drives Riboflavin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Riboflavin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .